haemophilia B
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients
... IB1001 was well tolerated as there were no reports of deaths, al- lergic reactions, anaphylaxis, thromboembolic events or related SAEs. The most common ADR was headache (2.6% of subjects). There were no reports of FIX ...
9
Haemophilia B in Five Nigerian Siblings
... Haemophilia B (HB) and haemophilia A (HA) are bleeding disorders inherited corresponding to x- linked recessively inheritance pattern [1]. They result from a quantitative and/or a qualitative ...
7
Inhibitor development in non-severe haemophilia across Europe
... non-severe haemophilia A, 14 (36%) of inhibitors were observed in patients with moderate haemophilia (FVIII activity 1-5%) and 25 (64%) in patients with mild haemophilia (FVIII activity ...mild ...
17
A STUDY OF HAEMOPHILIA IN MAHARASHTRA
... of haemophilia A to haemophilia B patients was ...severe haemophilia A patients were under 20 years of ...severe haemophilia A patients above 20 ...the haemophilia clinics, and ...
15
Issues in pediatric haemophilia care
... with haemophilia A and every third day or twice weekly for patients with haemophilia ...for Haemophilia Management based on the collabor- ation of 23 paediatricians from 16 European countries, have ...
5
Clinico-Hematological Profile and Iron Studies in Haemophilia Patients in Government Royapettah Hospital
... The dose calculation for factor IX is different from that of Factor VIII as the intravascular recovery of factor IX is only 50%. This is probably due to the binding of Factor IX to collagen type IV in the vessel wall. ...
131
Investigated the hospital utilization and medical resource usage of haemophilia A and B in Taiwan: 2001 2010
... grouped haemophilia patient’s muscu- loskeletal system together and others to another ...with haemophilia A and factor IX for patients with haemophilia B), either on a routine basis with sche- ...
8
Clinical Profile of Haemophilia In Children in A Tertiary Care Hospital
... in Haemophilia A and 4.1% cases in Haemophilia B 30 ...severe haemophilia, they reported only 5% cases with joint or muscle bleeding in severely affected cases, 21% cases in moderately ...
7
The cost of severe haemophilia in Europe: the CHESS study
... of haemophilia A patients relative to that of haemo- philia B in the CHESS cohort (approximately ...between haemophilia A and B is a topic of ongoing research; current evidence suggests that ...
8
HAEMOPHILIA: AN OVERVIEW
... Haemophilia also called hemophilia, is a mostly inherited, genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. This results in people bleeding longer after an ...
10
The relationship between target joints and direct resource use in severe haemophilia
... severe haemophilia in Europe, specifically regarding the cost of management of individuals with musculoskel- etal complications, and in particular those patients receiv- ing suboptimal therapy ...
7
Barriers and perceived limitations to early treatment of hemophilia
... Hemophilia is a rare, inherited, X-chromosome-linked bleeding disorder resulting from a deficiency of clotting factor VIII (hemophilia A) or factor IX (hemophilia B). Inhibitors to clotting factors VIII and IX ...
8
Two decades of haemophilia treatment in The Netherlands, 1972-1992
... Nonetheless, m 1992 the absence from school m patients with severe or moderately severe haemophilia was on average still 2-3 days higher than in patients with mild haemophilm, and sick l[r] ...
7
Pai-McMaster-Guideline-2016.pdf
... Two Guideline panel meetings were held, with support from and direct involvement of the Core Methods Group: June 2014 in Milwaukee, WI and May 2015 in Chicago, IL. The goals of the first face-to-face panel meeting were ...
11
The molecular diversity of the hepatitis C virus in patients with haemophilia
... with haemophilia have been exposed to thousands of donors when they received unsterilised clotting factor concentrates prior to the introduction of sterilisation procedures in 1985 (Lee et al, ...1985). ...
205
Treatment of Haemophilia A by Replacement Therapy using Factor VIII Inhibitors
... The quality of factor VIII gene is spotted by the presence on the end of the lengthy arm of chromosomes X. it includes 186,000 base sets disseminated between the 26 exons and the 25 introns. The result of this quality of ...
7
Studies of HIV and HCV co-infection in the context of haemophilia
... HCV is not usually directly cytopathic and hepatic damage appears to arise from the destruction of infected hepatocytes (Ferrari et al, 1999). The release o f lytic granules or Fas/FasL interactions by CD8+ CTLs can kill ...
284
Blood borne virus infection and immune modulation in boys with haemophilia A
... FVIII were used in the United Kingdom to treat haemophilia and von W illebrand’s disease and this had risen to 160 million units by 1994 (UK H aem ophilia Centre D irectors Annual Returns 1994). In the 1970’s, ...
403
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
... Figure 3 Efficacy of PEGLip-formulated FVIIa in preclinical experiments and a clinical trial. A) Efficacy in an animal model. Hemophilic mice were injected with PEGLip-FVIIa, standard FvIIa (both 10 µg/mouse), or saline. ...
11
Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency
... Group. Intestinal surgery with activated recombinant factor VII prophy- laxis in patients with haemophilia A and high responding inhibitors: a report of five cases. Blood Coagul Fibrinolysis. 2004;15(8):687–691. ...
13